11 recruiting, 3 active not recruiting, 3 not yet recruiting, 3 unknown. 10 Phase 1, 10 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Gastroesophageal-junction Cancer: new trials by email Literature Review of Gastroesophageal-junction Cancer trials Research Report on Gastroesophageal-junction Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer Cadonilimab - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 37 | 2026-05-27 | 2026-09-23 |
| A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer Adebrelimab Injection, SHR-A1811 for Injection, SHR-A1904 for Injection - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 200 | 2025-08-28 | 2026-01-09 |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas DR-0202 - Triple Negative Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Recruiting | Dren Bio | 96 | 2025-06-03 | 2026-01-07 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer HLX22, Pembrolizumab, Trastuzumab - Gastroesophageal-junction Cancer, Monoclonal Antibody | Phase 3 | Recruiting | Shanghai Henlius Biotech | 550 | 2024-11-22 | 2026-02-27 |
| Registry for Esophageal and Gastroesophageal Junction Cancer EORTC QLQ-C30 questionnaire, QLQ-OGS25 questionnaire - Gastroesophageal-junction Cancer, Esophageal Cancer | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2024-08-12 | 2026-05-22 | |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors BL-M07D1 - Endometrial Cancer, Cervical Cancer | Phase 1 | Recruiting | SystImmune Inc. | 280 | 2024-02-09 | 2026-10-13 |
| IKS014 in Advanced Solid Tumors That Express HER2 IKS014 - Breast Cancer, Gastric Cancer | Phase 1 | Recruiting | Iksuda Therapeutics Ltd. | 165 | 2023-09-14 | 2026-09-28 |
| Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction Nivolumab, Trastuzumab deruxtecan - Esophageal Adenocarcinoma, Esophageal Cancer | Phase 2 | Active not recruiting | Brown University | 1 | 2023-07-14 | 2026-04-21 |
| Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors AI-061 - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Completed | OncoC4, Inc. | 18 | 2023-07-11 | 2026-09-14 |
| Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma LB1908 - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 | Active not recruiting | Legend Biotech USA Inc | 56 | 2023-04-18 | 2026-09-02 |
| Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma Tislelizumab, S-1, Oxaliplatin - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 140 | 2023-03-15 | 2023-04-19 |
| TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy Tcrx T cell - Gastric Cancer, Gastroesophageal-junction Cancer | Early Phase 1 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2023-03-01 | 2023-02-16 |
| A Clinical Study of Laparoscopic Proximal Gastrectomy Based on PTST(Parachute-tunnel- Style Technique) Esophagogastric Anastomose. PTST(parachute-tunnel-style technique)for esophagogastrostomy - Gastroesophageal-junction Cancer, Proximal Gastrectomy | Not applicable | Unknown | Tang-Du Hospital | 100 | 2023-01-01 | 2024-01-23 |
| Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes IBI315, Oxaliplatin, Capecitabine - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 45 | 2023-01-01 | 2022-11-08 |
| Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody - Adenocarcinoma, Stomach Neoplasm | Phase 2 | Recruiting | Fudan University | 55 | 2023-01-01 | 2023-11-08 |
| XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma Anlotinib hydrochloride capsule, Penpulimab Injection, XELOX - Carcinoma, Gastrointestinal Diseases | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 80 | 2022-03-16 | 2023-11-07 |
| Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 1 / Phase 2 | Unknown | Hallym University Medical Center | 42 | 2022-03-01 | 2022-07-05 |
Showing 20 of 23. Sign in to see all of them.
Stomach Neoplasms (19) · Esophageal Neoplasms (7) · Endometrial Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Ovarian Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Anus Neoplasms (1)
Digestive System Neoplasms (21) · Neoplasms (21) · Neoplasms by Site (21) · Digestive System Diseases (20) · Gastrointestinal Diseases (20) · Gastrointestinal Neoplasms (20) · Stomach Diseases (19) · Head and Neck Neoplasms (8) · Esophageal Diseases (7) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Skin Diseases (5)
Oxaliplatin (5) · Capecitabine (3) · pembrolizumab (3) · Nivolumab (2) · Trastuzumab (2) · Albumin-Bound Paclitaxel (1) · Drug Therapy (1) · Fluorouracil (1) · Folfox protocol (1) · Gemcitabine (1) · Injections (1) · Metastasectomy (1) · Paclitaxel (1) · Peritoneal Lavage (1) · Radiation (1)
Memorial Sloan Kettering Cancer Center (2) · SystImmune Inc. (2) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (2) · Brown University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dren Bio (1) · Fudan University (1) · Hallym University Medical Center (1) · Henan Cancer Hospital (1) · Iksuda Therapeutics Ltd. (1) · Jazz Pharmaceuticals (1) · Legend Biotech USA Inc (1) · Merus B.V. (1) · OncoC4, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
United States (12) · China (6) · Australia (3) · Italy (2) · South Korea (2) · Spain (2) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Greece (1)
Charlie Qi, MD (1) · Dae Young Zang, Dr (1) · Daniela Molena, MD (1) · Howard Safran, MD (1) · James O'Leary, MD (1) · Lars Bo Svendsen, Prof., MD., DMSc. (1) · Manish A Shah, MD (1) · Michael Patrick Achiam, MD. phD. (1) · Rohit Joshi, MD (1) · Rune Broni Strandby, Junior researcher (1) · Sarah Tannenbaum, MD, MSc (1) · Silke Thiele, MD (1) · Wan Jen Hong, MD (1)
2017 (1)